OBJECTIVES:  Although ovarian cancer has been widely studied, there is very little documentation of patient reported outcomes (PRO) for patients with platinum-sensitive ovarian cancer (PSOC).  Initial therapy for ovarian cancer typically consists of surgery followed by platinum-based chemotherapy.  Patients are considered platinum-sensitive if disease recurrence occurs more than 6 months after completion of platinum-based treatment.  The objective of this literature review was to obtain a clear picture of patient reported outcomes (PROs) including health related quality of life (HRQoL), patient preferences, and health status utility for patients with PSOC.  METHODS: A systematic literature review of the peer-reviewed literature was conducted in Medline and Embase using the Cochrane approach.  Studies reporting and analyzing PROs, HRQoL, patient preferences, and health status utility in patients with PSOC over the past 10 years were identified.   RESULTS: The review identified 19 studies reporting PROs for PSOC patients, of which 9 were PSOC only, 7 were a combination of platinum-sensitive and resistant patients and 3 were platinum-treated recurrent patients. Of these 19 studies, there was a wide variation, with limited commonality, on the types of treatment regimens reported.  In general, QoL did not differ between therapies for PSOC patients.  However, in one study when docetaxel and carboplatin were given sequentially vs. in combination, an improvement in QoL was demonstrated. Another study showed that statistically significant higher QoL scores were found in pegylated liposomal doxorubicin treated patients than in gemcitabine patients.   CONCLUSIONS:  Given the limited number of PSOC references and variations in treatment regimens, it was difficult to identify common themes in patient preferences and PROs for this patient population.  PSOC patients' preferences and perceptions of treatment are important; however, this information is missing in the evidence base.  Further research is needed to identify treatment options which improve QoL and add value to PSOC patients' treatment experience.